Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gregory Piazza, M.D.

Co-Author

This page shows the publications co-authored by Gregory Piazza and Behnood Bikdeli.
Connection Strength

5.429
  1. Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. Contemp Clin Trials. 2022 Feb 21; 115:106714.
    View in: PubMed
    Score: 0.988
  2. Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. Thromb Haemost. 2021 Sep 16.
    View in: PubMed
    Score: 0.959
  3. Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. J Am Coll Cardiol. 2021 07 27; 78(4):408-411.
    View in: PubMed
    Score: 0.941
  4. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 10 19; 78(16):1635-1654.
    View in: PubMed
    Score: 0.241
  5. Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. J Thromb Haemost. 2021 12; 19(12):3080-3089.
    View in: PubMed
    Score: 0.240
  6. Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. J Am Heart Assoc. 2021 09 07; 10(17):e021467.
    View in: PubMed
    Score: 0.239
  7. Images in Vascular Medicine: Pulmonary embolism and acute aortic syndromes - Double trouble when vascular medicine emergencies meet. Vasc Med. 2022 02; 27(1):97-99.
    View in: PubMed
    Score: 0.237
  8. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021 04 27; 325(16):1620-1630.
    View in: PubMed
    Score: 0.233
  9. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thromb Haemost. 2022 Jan; 122(1):131-141.
    View in: PubMed
    Score: 0.233
  10. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 04 20; 77(15):1903-1921.
    View in: PubMed
    Score: 0.232
  11. Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Semin Thromb Hemost. 2020 Nov; 46(8):908-918.
    View in: PubMed
    Score: 0.225
  12. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thromb Res. 2020 12; 196:382-394.
    View in: PubMed
    Score: 0.224
  13. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020 Jul; 120(7):1004-1024.
    View in: PubMed
    Score: 0.219
  14. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 06 16; 75(23):2950-2973.
    View in: PubMed
    Score: 0.217
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.